BioSpace News Archive

Instrumentation Laboratory has received three IMV ServiceTrak Awards for 2020, including Best System Performance, for the second consecutive year, Best Service in the Coagulation category, and Best Customer Satisfaction, in the newly added Blood Gas category.

BioMarin Pharmaceutical Inc. announced that Jeff Ajer, Executive Vice President and Chief Commercial Officer, and Brian Mueller, Executive Vice President, Chief Financial Officer will participate in the 2020 Wedbush PacGrow Healthcare Virtual Conference on August 11, 2020 at 10:55am ET

VistaGen Therapeutics, Inc. (Nasdaq: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (CNS) disorders, today announced the underwriters of its previously announced public offering of common stock exercised and closed their over-allotment option, resulting

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that Sandy Macrae, CEO of Sangamo, will present at the 2020 Wedbush PacGrow Healthcare Conference on August 12, 2020 at 2:55 p.m. Eastern Time. The presentation will be webcast live and may be accessed via a link on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations . About S

Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company primarily focused on developing novel treatments for endocrine diseases with significant unmet needs, today provided a corporate update and reported financial

Announced Path Forward for VS-6766 and Defactinib Combination Following Meeting with FDA Phase 2 Registration-Directed Trials Expected to Commence by Year End 2020 in Both Low-Grade Serous Ovarian Cancer and KRAS Mutant Non-Small Cell Lung Cancer Company Monetizes COPIKTRA ® (duvelisib) Providing Cash Runway Until at Least 2024 BOSTON--( BUSINESS WIRE )-- Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutic

Verastem Will Receive $70 Million Up-Front with Total Deal Value Up to $311 Million, Plus Double-Digit Sales Royalties Upon Closing, Verastem’s Current Programs Will Be Funded Until At Least 2024 to Develop VS-6766 and Defactinib in Low-Grade Serous Ovarian Cancer and KRAS Mutant Non-Small Cell Lung Cancer Phase 2 Registration-Directed Trials Expected to Commence by Year End 2020 in Both Low-Grade Serous Ovarian Cancer and KRAS Mutant Non-Smal

Hancock Jaffe Laboratories, Inc. today announced that HJLI has received formal notification from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has evidenced full compliance with the stockholders’ equity requirement

Preclinical data for TNX-1800, a Vaccine Candidate to Protect Against COVID-19, Expected in Fourth Quarter 2020 Interim Analysis Results for Phase 3 RELIEF Trial of TNX-102 SL for the Management of Fibromyalgia Expected in September 2020 Topline Data for RELIEF Trial Expected in Fourth Quarter 2020

OrthoPediatrics Corp., a company focused exclusively on advancing the field of pediatric orthopedics, announced that Mark Throdahl, Chief Executive Officer, Fred Hite, Chief Operating Officer and Chief Financial Officer, and Dave Bailey, President, are scheduled to participate in the 5th Annual Needham Virtual Med Tech 1x1 Conference.